

As many as 1 in 10 Aboriginal and Torres Strait Islander adults with diabetes have vision impairment due to Diabetic Retinopathy.

Identifying people with diseases at an early stage can help avoid disease complications. In many cases, screening can help avoid onset of the disease altogether.

Diabetic Retinopathy is often at an advanced stage when symptoms become noticeable. The Artelus AI product not only identifies the presence of Diabetic Retinopathy but it can detect it at a very early stage.

Recognising that most AI solutions require access to the internet, Artelus developed a solution where the algorithms are embedded on chips. Geographies that don't have internet access are no longer deprived of AI-powered healthcare screening. The algorithms read medical images in under 30 seconds and provide immediate results.

The product is currently used in India, Dubai and the UK. It launched in Australia in late 2019 and currently running as a pilot site with BHVI in the Aboriginal Medical Service Redfern.

With Artelus' state-of-the-art deep learning algorithms, clinics can provide screening for Diabetic Retinopathy in remote areas that are lacking healthcare facilities. Technology ensures wider reach and lower cost resulting in better outcomes for everyone involved in the healthcare system.

#### **SHORT BIO FOR JAYNE SHAW (PRESENTING AUTHOR)**

Jayne Shaw trained as a Registered Nurse and subsequently

- established an Australian / International health consulting business
- was Co-founder of Vision Group (listed on ASX).

Jayne has sat on private healthcare boards - cardiology, ophthalmology, orthopaedics, women's health.

Current Board positions are BCAL Diagnostic's Chair, Woolcock Institute, The Hareda Foundation.